Table 3:

Treatment exposure patterns in post-ARTA NGS group

	L702H	T787A	H875Y	W743C
Prior treatment exposures– no (%)
Abiraterone	34 (85.0)	23 (95.8)	11 (84.6)	2 (40.0)
Apalutamide	2 (5.0)	2 (8.3)	0 (0.0)	0 (0.0)
Bicalutamide	14 (35.0)	7 (29.2)	5 (38.5)	0 (0.0)
Cabazitaxel	16 (40.0)	7 (29.2)	3 (23.1)	0 (0.0)
Docetaxel	19 (47.5)	10 (41.7)	5 (38.5)	1 (20.0)
Enzalutamide	33 (82.5)	11 (45.8)	11 (84.6)	4 (80.0)
Number of prior ARTA exposure – no (%)
1	14 (35.0)	14 (58.3)	4 (30.8)	4 (80.0)
2	24 (60.0)	6 (25.0)	8 (61.5)	1 (20.0)
3+	2 (5.0)	4 (16.7)	1 (7.7)	0 (0.0)